A study found that the sa-mRNA COVID-19 vaccine is more effective than Comirnaty against various variants at one-sixth the dose. The sa-mRNA vaccine Kostaive is approved in Japan. ARCT-2301 also shows superior immunogenicity over Comirnaty.